Dr. Roni Dodiuk-Gad

Dr. Dodiuk-Gad earned an M.D. degree, Cum Laude, from the Rappaport Faculty of Medicine, Technion, Haifa, Israel in 2002 and received an award of excellence for her M.D. thesis. She completed with excellence a residency in Dermatology, conducted 3 years of clinical fellowship in ‘Advanced Medical Dermatology’ in the Dermatology Division, Sunnybrook Health Sciences Centre under the supervision of Professor Neil H. Shear at the University of Toronto, Canada and upon completion became a research fellow at the University of Toronto

Dr. Roni P. Dodiuk-Gad is currently the vice-head of the Dermatology Department, Emek Medical Center, a Clinical Assistant Professor in the Bruce Rappaport Faculty of Medicine, Technion – Institute of Technology, Israel and a Research Fellow at the University of Toronto, Canada

Dr. Dodiuk-Gad is a global opinion leader on 2 topics; adverse cutaneous drug reactions and Darier disease. She is mentoring students in Israel and Canada leading research teams on these topics. In her research on Darier disease she discovered important unknown clinical manifestations of the disease and novel genetic mutations and in her research on adverse cutaneous drug reactions she found major long-term emotional and physical complications of survivors of Stevens – Johnson syndrome and Toxic Epidermal Necrolysis (SJS/TEN), discovered major gaps in the management of patients with Toxic Epidermal Necrolysis (TEN) in North America and designed and published assessment and treatment protocol for patients with TEN. She was the Vice-Chair of the 9th International Congress on Cutaneous Adverse Drug Reactions-iSCAR2015 in 2015, Vancouver, Canada and a member of the organizing committee of the conference “Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis 2017: Building Multidisciplinary Networks to Drive Science & Translation” in 2017, Orlando, Florida, USA. On November 2018, Dr. Dodiuk-Gad and Professor Shear published as co-editors the first edition of a book by Springer-Nature, “Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends”. She is currently in the leadership team of an international collaboration that is funded by an NIH grant, a randomized controlled trial for the treatment of Stevens –Johnson syndrome and toxic epidermal necrolysis

Dr. Dodiuk-Gad received numerous academic grants and awards; in 2012 she was designated as “Promising Young Investigator” by the Canadian Dermatology Association, in 2015 she was invited to give a Rising Star Talk in the 23rd World Congress of Dermatology, and in 2018, she was chosen by Technion Alumni Association as one of the 40 most promising young graduated of the Technion – Institute of Technology, Israel

Darier disease – new insights